vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v24i4.2935vsp-3810Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSOverlap-синдром (сочетание локализованной склеродермии и дискоидной красной волчанки) у ребенка: клинический случайOverlap Syndrome (Localized Scleroderma and Discoid Lupus Erythematosus) in a Child: Case Studyhttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич, доктор медицинских наук, руководитель НИИ детской дерматологии, заведующий отделением дерматологии и аллергологии; профессор кафедры дерматовенерологии и косметологии; профессор кафедры педиатрии и детской ревматологии

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1

тел.: +7 (495) 967-14-20

Moscow

m_nn2001@mail.ruhttps://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexandr I.

Москва

Moscow

https://orcid.org/0009-0001-9498-8990АльшевскийЯ. Ю.AlshevskiyYaroslav Yu.

Москва

Moscow

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва

Moscow

https://orcid.org/0000-0001-5739-0941ЛеоноваМ. А.LeonovaMariya A.

Москва

Moscow

https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва

Moscow

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва

Moscow

https://orcid.org/0009-0003-5367-3268ПавловаЕ. С.PavlovaEkaterina S.

Москва

Moscow

https://orcid.org/0000-0003-4773-2842КатунинаО. Р.KatuninaOksana R.

Москва

Moscow

https://orcid.org/0000-0002-1107-8693КуликовК. А.KulikovKirill A.

Москва

Moscow

Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академияРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential AffairsRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationЦентральная государственная медицинская академияРоссияCentral State Medical Academy of Department of Presidential AffairsRussian Federation202518092025244262266Copyright © Мурашкин Н.Н., Материкин А.И., Альшевский Я.Ю., Епишев Р.В., Леонова М.А., Опрятин Л.А., Иванов Р.А., Павлова Е.С., Катунина О.Р., Куликов К.А., 20252025Мурашкин Н.Н., Материкин А.И., Альшевский Я.Ю., Епишев Р.В., Леонова М.А., Опрятин Л.А., Иванов Р.А., Павлова Е.С., Катунина О.Р., Куликов К.А.Murashkin N.N., Materikin A.I., Alshevskiy Y.Y., Epishev R.V., Leonova M.A., Opryatin L.A., Ivanov R.A., Pavlova E.S., Katunina O.R., Kulikov K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3810

Обоснование. Сочетание системной склеродермии и системной красной волчанки описано в литературе достаточно подробно. Перекрест локализованных форм склеродермии и дискоидной красной волчанки у детей описан в единичных клинических наблюдениях. Описание клинического случая. Представлен редкий клинический случай оverlap-синдрома, продемонстрированы результаты медикаментозной терапии, освещаются вопросы дифференциальной диагностики и патогенетические особенности патологии. Заключение. Диагностика оverlap-синдромов представляет значительные трудности. Несвоевременная верификация диагноза приводит к назначению малоэффективной терапии. В результате развиваются стойкие функциональные и косметические дефекты кожи, оказывающие негативное влияние на качество жизни пациентов.

Background. The combination of systemic scleroderma and systemic lupus erythematosus is described sufficiently detailed in the literature. However, overlap of localized forms of scleroderma and discoid lupus erythematosus in children is described only in single clinical observations. Case description. Rare case study of overlap syndrome is presented, the results of drug treatment are demonstrated, differential diagnosis issues and disease pathogenetic features are highlighted. Conclusion. Diagnosis of overlap syndromes presents significant difficulties. Its untimely verification leads to ineffective management. As a result, persistent functional and cosmetic skin defects develop, leading to negative impact on patients' quality of life.

клинический случайoverlap-синдромлокализованная склеродермиядискоидная красная волчанкацитокиныcase studyoverlap syndromelocalized sclerodermadiscoid lupus erythematosuscytokinesОтсутствует.Not specified.ReferencesMagro CM, Schwartz Z. Intralesional overlap syndrome: Sclerodermic lupus panniculitis and sclerodermic discoid lupus erythematosus. JAAD Case Rep. 2020;6(2):146–149. doi: https://doi.org/10.1016/j.jdcr.2019.12.006Magro CM, Schwartz Z. Intralesional overlap syndrome: Sclerodermic lupus panniculitis and sclerodermic discoid lupus erythematosus. JAAD Case Rep. 2020;6(2):146–149. doi: https://doi.org/10.1016/j.jdcr.2019.12.006Batu ED, Günalp A, Şahin S, et al. Pediatric mixed connective tissue disease versus other overlap syndromes: a retrospective multicenter cohort study. Rheumatol Int. 2023;43(8):1485–1495. doi: https://doi.org/10.1007/s00296-023-05300-xBatu ED, Günalp A, Şahin S, et al. Pediatric mixed connective tissue disease versus other overlap syndromes: a retrospective multicenter cohort study. Rheumatol Int. 2023;43(8):1485–1495. doi: https://doi.org/10.1007/s00296-023-05300-xDenton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103): 1685–1699. doi: https://doi.org/10.1016/S0140-6736(17)30933-9Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103): 1685–1699. doi: https://doi.org/10.1016/S0140-6736(17)30933-9Scherlinger M, Guillotin V, Truchetet ME, et al. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun Rev. 2018;17(6):625–635. doi: https://doi.org/10.1016/j.autrev.2018.01.012Scherlinger M, Guillotin V, Truchetet ME, et al. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun Rev. 2018;17(6):625–635. doi: https://doi.org/10.1016/j.autrev.2018.01.012Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301(2): 93–98. doi: https://doi.org/10.1007/s00403-008-0894-6Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301(2): 93–98. doi: https://doi.org/10.1007/s00403-008-0894-6Lu J, Liu Q, Wang L, et al. Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling. Lab Invest. 2017;97(9):1121. doi: https://doi.org/10.1038/labinvest.2017.43Lu J, Liu Q, Wang L, et al. Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling. Lab Invest. 2017;97(9):1121. doi: https://doi.org/10.1038/labinvest.2017.43Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14(3):R144. doi: https://doi.org/10.1186/ar3877Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14(3):R144. doi: https://doi.org/10.1186/ar3877Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73(2):326–334. doi: https://doi.org/10.1016/j.cyto.2015.01.031Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73(2):326–334. doi: https://doi.org/10.1016/j.cyto.2015.01.031Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019; 15(9):519–532. doi: https://doi.org/10.1038/s41584-019-0272-0Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019; 15(9):519–532. doi: https://doi.org/10.1038/s41584-019-0272-0Cardoneanu A, Burlui AM, Macovei LA, et al. Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: Why IL-6? Biomedicines. 2022;10(2):318. doi: https://doi.org/10.3390/biomedicines10020318Cardoneanu A, Burlui AM, Macovei LA, et al. Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: Why IL-6? Biomedicines. 2022;10(2):318. doi: https://doi.org/10.3390/biomedicines10020318Piroozmand A, Dabbaghmanesh MH, Omrani GR, et al. Serum interleukin-6 level and its association with pulmonary involvement in progressive systemic sclerosis: a case-control study. Clin Mol Allergy. 2023;21(1):7. doi: https://doi.org/10.1186/s12948-023-00188-1Piroozmand A, Dabbaghmanesh MH, Omrani GR, et al. Serum interleukin-6 level and its association with pulmonary involvement in progressive systemic sclerosis: a case-control study. Clin Mol Allergy. 2023;21(1):7. doi: https://doi.org/10.1186/s12948-023-00188-1Shima Y. Cytokines involved in the pathogenesis of systemic sclerosis: potential therapeutic targets. Cells. 2021;10(5):1104. doi: https://doi.org/10.3390/cells10051104Shima Y. Cytokines involved in the pathogenesis of systemic sclerosis: potential therapeutic targets. Cells. 2021;10(5):1104. doi: https://doi.org/10.3390/cells10051104Al-Gburi S, Moinzadeh P, Krieg T. Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives. Sclerosis. 2025;3(2):17. doi: https://doi.org/10.3390/sclerosis3020017Al-Gburi S, Moinzadeh P, Krieg T. Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives. Sclerosis. 2025;3(2):17. doi: https://doi.org/10.3390/sclerosis3020017Bellando-Randone S, Della-Torre E, Balanescu A. The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic? J Scleroderma Relat Disord. 2021;6(3):227–235. doi: https://doi.org/10.1177/23971983211039421Bellando-Randone S, Della-Torre E, Balanescu A. The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic? J Scleroderma Relat Disord. 2021;6(3):227–235. doi: https://doi.org/10.1177/23971983211039421Xing X, Yang J, Yang X, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013;8(12):e85032. doi: https://doi.org/10.1371/journal.pone.0085032Xing X, Yang J, Yang X, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013;8(12):e85032. doi: https://doi.org/10.1371/journal.pone.0085032Shima Y. Interleukin-6 in the Pathogenesis of Systemic Sclerosis. In: Systemic Sclerosis. Takehara K, Fujimoto M, Kuwana M, eds. Tokyo: Springer; 2016. pp. 103–115. https://doi.org/10.1007/978-4-431-55708-1_7Shima Y. Interleukin-6 in the Pathogenesis of Systemic Sclerosis. In: Systemic Sclerosis. Takehara K, Fujimoto M, Kuwana M, eds. Tokyo: Springer; 2016. pp. 103–115. https://doi.org/10.1007/978-4-431-55708-1_7Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8(1):402. doi: https://doi.org/10.1038/s41392-023-01620-3Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8(1):402. doi: https://doi.org/10.1038/s41392-023-01620-3Chasset F, Frances C. Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive. Drugs. 2019;79(11):1199–1215. doi: https://doi.org/10.1007/s40265-019-01151-8Chasset F, Frances C. Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive. Drugs. 2019;79(11):1199–1215. doi: https://doi.org/10.1007/s40265-019-01151-8Inamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Pediatr Dermatol. 2013;30(6):e191–e193. doi: https://doi.org/10.1111/j.1525-1470.2012.01882.xInamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Pediatr Dermatol. 2013;30(6):e191–e193. doi: https://doi.org/10.1111/j.1525-1470.2012.01882.xQayoom S, Rather S, Manzoor S, Sameen F. Evaluation of corticosteroid and methotrexate therapy in the treatment of moderate to severe localized scleroderma (morphea) — A 5 year study in a teaching hospital of North India. Int J Contemp Med Res. 2019;6(5):E1–E4. doi: https://doi.org/10.21276/ijcmr.2019.6.5.11Qayoom S, Rather S, Manzoor S, Sameen F. Evaluation of corticosteroid and methotrexate therapy in the treatment of moderate to severe localized scleroderma (morphea) — A 5 year study in a teaching hospital of North India. Int J Contemp Med Res. 2019;6(5):E1–E4. doi: https://doi.org/10.21276/ijcmr.2019.6.5.11

The authors declare that there are no conflicts of interest present.